Janney Montgomery Scott LLC Sells 8,089 Shares of Gilead Sciences, Inc. (GILD)

Janney Montgomery Scott LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 168,285 shares of the biopharmaceutical company’s stock after selling 8,089 shares during the period. Janney Montgomery Scott LLC’s holdings in Gilead Sciences were worth $12,993,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Reilly Financial Advisors LLC lifted its holdings in Gilead Sciences by 98.3% in the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Gilead Sciences in the second quarter worth about $132,000. Brand Asset Management Group Inc. acquired a new stake in Gilead Sciences in the second quarter worth about $139,000. TRUE Private Wealth Advisors acquired a new stake in Gilead Sciences in the third quarter worth about $174,000. Finally, Truvestments Capital LLC acquired a new stake in Gilead Sciences in the third quarter worth about $210,000. Institutional investors and hedge funds own 78.09% of the company’s stock.

GILD stock opened at $71.18 on Friday. The company has a quick ratio of 3.39, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a one year low of $64.27 and a one year high of $89.54. The stock has a market cap of $93.76 billion, a price-to-earnings ratio of 11.29, a PEG ratio of -2.81 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The company had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same period in the prior year, the firm earned $2.27 earnings per share. Sell-side analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is presently 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 150,000 shares of company stock valued at $11,087,500 over the last ninety days. Insiders own 1.30% of the company’s stock.

A number of equities research analysts have weighed in on GILD shares. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Wednesday, July 18th. Robert W. Baird downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a report on Thursday, July 26th. Wells Fargo & Co upped their price target on shares of Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Morgan Stanley upped their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a report on Thursday, July 26th. Finally, Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $87.84.

TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/11/10/janney-montgomery-scott-llc-sells-8089-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Marijuana Stocks

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply